Notice ID: ca07da47c0334361ade7f7e6f920b6a0Presolicitation
NextSeq 1000
Archived on July 2, 2026. Original response deadline: . Full description on SAM.gov.
Description
The Defense Health Agency Contracting Activity (DHACA) in Fort Detrick, MD intends to negotiate on a sole source basis (IAW RFO 12.102(a)) with ILLUMINA, INC 5200 Illumina Way, San Diego, CA 9212-4616 as the only responsible source that can provide the NextSeq 1000 Sequencing System. This is a Presolicitation notice in accordance with RFO 5.101.
The equipment provided by ILLUMINA INC is the only source that provides DHACA with the NextSeq 1000 Sequencing System used at the Armed Forces Medical Examiner System DNA Operations (AFMES-DNA OPS) to support their mission. Its fast, integrated DNA-to-analysis workflow allows for the rapid sequencing of targeted panels, whole mitochondrial genomes, and supports single nucleotide polymorphism (SNP) analysis in a single run.
This acquisition is being conducted under simplified acquisition procedures. There are no set-aside restrictions for this requirement. The intended procurement will be classified under North American Industry Classification System (NAICS) 334516 with a Small Business Size Standard of 1,000 employees. This presolicitation notice is not a request for competitive proposals and no solicitation document exists for this requirement. However, any parties interested in responding to this notice shall submit technical data, including cost, sufficient to determine capability in providing the same service. All capability statements received by closing of this notification of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
Based on the above information, the only technically acceptable subscription can be provided by ILLUMINA INC .
Submit email capability statements (using PDF, MS Word, Excel attachments) to Alicia Maldonado Torres at alicia.maldonadotorres.civ@health.mil. Statements are due no later than 12:00 P.M. EST on 1 July 2026. No phone calls will be accepted.
Overview
Agency:
Department of WarDEFENSE HEALTH AGENCY (DHA)
Office:ARMY MED RES ACQ ACTIVITY
Posted:June 17, 2026
NAICS:334516: Analytical Laboratory Instrument Manufacturing
Last Updated:Aug 21, 2026
PSC:6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES
Set-Aside:No Set aside used
Type:Presolicitation
Place of Performance:Dover AFB, Delaware, 19902
Award Overview
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
Documents
Showing 1 of 1 items
Document | Source | Agency | Posted Date | File Size | Actions | |
|---|---|---|---|---|---|---|
| Presolicitation | DEFENSE HEALTH AGENCY (DHA) | Jun 17, 2026 | 175.61 KB |
Lifecycle
Solicitation:
FY26-0778- Pre-Solicitation
Formal solicitation typically follows within 30–60 days. (estimate)
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
The Defense Health Agency Contracting Activity (DHACA) intends to award a Firm Fixed Price, sole source Contract on behalf of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to DNA Script Inc, located in Cambridge, MA, under the authority of 41 U.S.C. 1901, as prescribed in RFO FAR 12.102(b) Restricting Competition for acquisitions valued over the SAT. This requirement is for the acquisition of 1 benchtop DNA synthesizer system with a preventative maintenance support contract for an additional 4 years. The benchtop unit shall meet the following minimum essential characteristics: 1. The synthesizer table-top dimensions must not exceed: 48’’ x 26’’ x 29’’. The required vacuum cabinet (freestanding) is 33’’ x 26’’ x 26’’ (inches). 2. The synthesizer shall have same-day throughput e.g. 96 oligos of 20 nucleotides in length in approximately 6 hours and 120 nucleotides in less than 24 hours 3. The synthesizer shall synthesize oligos labeled with fluorophores, quenchers, or biotin with the use of appropriate reagent kits with up to 5 colors in parallel. 4. The synthesizer shall be fully automated: oligos are synthesized, quantified, and normalized in a single synthesis run without user interaction following an approximate range of 15 to 30 minutes of setup. 5. The synthesizer shall have console software that can be installed and hosted on a stand-alone, off-network computer connected to the synthesizer. 6. The synthesizer shall have no harsh organic solvents: the product uses biochemistry, composed of water-based reagents, proprietary enzymes, and proprietary nucleotides that are typically compliant with standard laboratory waste management systems. 7. The synthesizer can perform without any specific environmental control (no need for Argon or any Gas). 8. The synthesizer should have an output power capacity of 1800 W / 2200 VA, 120 VAC input/output voltage and NEMA 5-20P input connection. 9. The synthesizer should produce oligos as they occur in biology, producing oligos that are free of molecular defects or blemishes. 10. The data management software shall provide user authentication features to include: password complexity requirements; automatic logout; limited login attempts; and account inactivity period. 11. The data management software shall have full traceability for synthesis runs, quality control runs, instrument maintenance, reagent usage, user identification, and 5 years of support. 12. The synthesizer shall permit data export to a backup medium. 13. The contractor shall provide method validation services and on-site and off-site operator training, as well as on-site start up support. 14. The contractor shall provide onsite preventative and corrective maintenance for analyzers previously used in biocontainment laboratories (following decontamination). 15. The contractor shall be an Original Equipment Manufacturer (OEM) authorized dealer, authorized distributor, or authorized reseller for the quoted equipment such that OEM warranty and service are provided and maintained by the OEM. All software licensing, warranty, and services associated with the equipment shall be in accordance with OEM terms and conditions. DNA Script is the only vendor who has a benchtop DNA synthesizer capable of producing 96 oligonucleotides of 20 nucleotides in lengths in 6 hours and 120 nucleotides in length in 24 hours. DNA Script also has the capability of adding biotin, quenchers, and fluorescent molecules to the oligonucleotides for downstream applications, reducing the cost of targeting pathogens. DNA Script’s synthesizer is the only unit capable of meeting all the government’s minimum essential characteristics. The safety features built into the synthesizer protect users by reducing the use of hazardous chemicals, dedicated fume vents, and gas cylinders limiting exposer to stored chemicals. This announcement fulfills the synopsis requirement under RFO FAR 5.101(a). This notice of intent is NOT a request for quotations (RFQ) and no solicitation document exists for the requirement; however, if a vendor challenges the basis for this requirement, please submit a capability statement that includes sufficient detail and with convincing evidence that clearly demonstrates the capability to meet the governments requirement. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source procurement. Any other firms desiring consideration must submit capability statements and identify their interest and capability in providing these services. Responses to this notice must be received no later than 0900 Eastern Time, 2 November 2026. Capability statements shall be submitted via email ONLY as a Microsoft Word or Adobe PDF attachment to the following email addresses ryan.r.jorgensen.civ@health.mil and jayme.l.fletcher2.civ@health.mil. No phone calls will be accepted. | Special Notice | 334516 | No Set-Aside | 10/15/2026 | 11/02/2026 | Frederick, MD | |
1. Purpose The Defense Health Agency (DHA) is conducting market research to identify capable sources that can provide a complete, integrated multi-modality Transfusion-Transmitted Disease (TTD) testing solution for the Armed Services Blood Bank Center-Europe (ASBBC-EUR) located at Landstuhl Regional Medical Center (LRMC), Germany. This is a Request for Information (RFI) for market research and planning purposes only. It does not constitute a Request for Proposals (RFP), Request for Quotations (RFQ), or an invitation for bids. 2. Requirement Overview The Government requires the supply, installation, validation, training, ongoing maintenance, software support and upgrades, technical support, and reagent/consumable support for three complementary testing platforms capable of performing the full suite of U.S. Food and Drug Administration (FDA) required blood-donor screening assays: Immunohematology / ABO-Rh, Syphilis, Cytomegalovirus (CMV), Antibody Titer (example platform class: Beckman Coulter PK7400 or equivalent) Serology (example platform class: Abbott Alinity s or equivalent) – Human Immunodeficiency Virus (HIV) Antigen/Antibody Combo, Anti-Hepatitis C Virus (Anti-HCV), Hepatitis B Surface Antigen (HBsAg), Human T-lymphotropic Virus (HTLV) I/II, Anti-Hepatitis B Core (Anti-HBc), Chagas Nucleic Acid Testing (NAT) (example platform class: Grifols Procleix Panther / Ultrio Elite or equivalent) – HIV, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), West Nile Virus (WNV), Babesia Approximate annual volume is 6,000 whole-blood units (plus residual plasma and platelets as needed). All systems must be FDA Center for Biologics Evaluation and Research (CBER)-cleared/licensed for blood-donor screening. Dual-marked (FDA + CE) systems are preferred. FDA-only systems are acceptable provided they operate directly on German power sources (single-phase 230 V / 50 Hz) with no transformer required. Preferred approach: A single integrated multi-modality solution from one prime contractor (or formal teaming arrangement). If responding as a team, joint venture, or prime-subcontractor arrangement, clearly identify the lead entity, proposed roles, and commercial distribution authority for each platform. If market research demonstrates that a viable single-source or single-team solution is not reasonably available, the Government reserves the right to pursue separate Requests for Quotation (RFQs) / Requests for Proposal (RFPs) for individual modalities. 3. Site and Utility Constraints (Critical) Performance location is a basement laboratory at LRMC, Germany, with approximately 585 usable square feet available after existing laboratory functions remain in place. Key constraints that must be addressed in any response: Power: Single-phase 230 V / 50 Hz. Schuko connectors preferred. Respondents shall provide the potential continuous and peak power demand (amps and kilovolt-amperes) for every analyzer and any supporting equipment (uninterruptible power supply, water-treatment system, etc.) under full operational load. Water: All three platforms are assumed to require treated/purified water (reverse osmosis or equivalent, Clinical Laboratory Reagent Water or Type I preferred). Respondents must state exact water consumption footprint (gallons/liters per day) for each piece of equipment presented, purity specifications, estimated daily volume, and footprint of any required water-treatment system(s). Footprint: Provide exact dimensions, weight, and clearance requirements for all proposed equipment and any water-treatment equipment. Environmental: Ambient 18–28 °C, 20–80 % relative humidity typical. Confirm compatibility. Network & Data Infrastructure: Workstations will be equipped with standard RJ45 Ethernet network drops; all equipment data interfaces must operate within the existing DoD/DHA local area network environment, and no external commercial internet connections or vendor-installed wireless networks are permitted. 4. Contract Type Preferences Both lease (cost-per-test or cost-per-kit inclusive of reagents, ongoing maintenance, software support and upgrades, and technical support) and outright purchase solutions will be considered. The Government states a preference for leased equipment, particularly given the potential relocation noted below. 5. Potential Facility Relocation ASBBC-EUR may relocate to a new facility within the next 2–5 years. The new location will not exceed 50 km from the current site and, for planning purposes, should be treated as approximately 20 km. Respondents should address: How a lease structure would accommodate relocation or early termination. Residual value, buy-out, or transfer options for purchased equipment. Any additional costs or logistics associated with de-installation, transport, and re-installation at a new German location within the distances noted above. 6. Performance Location and Legal Framework All performance will occur on a U.S. military installation in the Federal Republic of Germany under the North Atlantic Treaty Organization (NATO) Status of Forces Agreement (SOFA). All applicable host-nation laws and U.S. laws and regulations will apply. Respondents must confirm ability to perform under these conditions and identify any existing in-country service capability, parts stocking locations, or technical personnel based in Germany or the European Union. 7. Correlation / Validation and Start-Up Costs Respondents should note that correlation and validation requirements must satisfy applicable U.S./DHA blood-bank standards as well as host-nation (German) expectations that the laboratory must meet. All reagents, quality-control materials, and related consumables required for initial correlation and validation shall be treated as part of the initial setup / installation cost and are not included in the ongoing test quantities or reagent volumes under the contract. 8. System for Award Management (SAM) Registration Interested parties must possess (or immediately begin obtaining) an active System for Award Management (SAM.gov) registration. Because this requirement is performed in Europe, respondents are specifically requested to state whether they currently maintain an active SAM registration with a European or NATO Commercial and Government Entity (CAGE) code. If not, parties that intend to respond to a future solicitation should begin the registration process now. 9. Information Requested Interested sources are requested to submit a brief capability statement (not to exceed 10 pages) addressing: a. Company name, CAGE code, Unique Entity Identifier (UEI), and point of contact, SAM registration status, including any European/NATO CAGE code. b. Confirmation of FDA CBER clearance/license status for each proposed platform. c. Whether a single integrated multi-modality solution (or formal teaming arrangement) can be offered. d. Lease and/or purchase pricing constructs (rough-order-of-magnitude acceptable at this stage), inclusive of ongoing maintenance and software support/upgrades. e. Potential continuous and peak power demand (amps and kilovolt-amperes) for the full proposed configuration. f. Water-treatment requirements, purity specifications, daily volume, and footprint (all three platforms assumed to require treated water). g. Equipment dimensions, weight, and site-preparation needs. h. Current in-country (Germany/European Union) service, parts, and technical support capability. i. Experience installing the same or equivalent platforms in European military, blood-center, or hospital environments. j. Ability to meet a Not-Later-Than operational date of 27 September 2027. k. Approach to ongoing maintenance, software support, and upgrades throughout the period of performance. l. Confirmation that reagents and quality-control materials for initial correlation/validation are included in start-up costs. m. Vendors shall detail all equipment IT and network requirements, including physical network connections, supported LIS/DBSS interface protocols (e.g., HL7, ASTM), any required middleware or server hardware, and whether remote diagnostics/internet connectivity is needed for system operation or vendor support. n. Any other information the respondent believes relevant to the Government’s acquisition planning. In addition to the capability information requested above, respondents are invited to offer brief observations or alternative solution concepts that could better address the site constraints, integrated multi-modality preference. Any such input is for market-research purposes only and will not be evaluated as a proposal. | Market Research | 334516 | No Set-Aside | 10/08/2026 | 10/21/2026 | Landstuhl, DE-RP | |
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Varian Medical Systems, Inc. Acquisition Description: The Clinical Center partners with the National Cancer Institute, Thoracic and Gastrointestinal Branch in offering diagnosis and treatment of cancer. The IntelliBlate Ximitry Probe is a specialized, single-use surgical instrument manufactured by Varian Medical Systems (a Siemens Healthineers company) designed for use with the IntelliBlate Microwave Ablation System. The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-27-000328) by 12:00 PM eastern standard time on 10/16/2026 to: valerie.gregorio@nih.gov. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. | Special Notice | 334516 | No Set-Aside | 10/09/2026 | 10/16/2026 | Bethesda, MD | |
This is a combined synopsis/solicitation for commercial products and commercial services prepared in accordance with the format Revolutionary FAR Overhaul (RFO) in Federal Acquisition Regulation (FAR) subpart 12.202, “Streamlined Procedures for Evaluation and Solicitation for Commercial Products and Commercial Services,” as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested, and a written solicitation document will not be issued. This solicitation is issued as an RFQ. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01 effective date 3/13/2026. This solicitation is unrestricted. The associated North American Industrial Classification System (NAICS) code for this procurement is 334516, with a small business size standard of 1000 employees. The FSC/PSC is 6515. VA New Jersey Health Care System’s Research and Development Service located at 385 Tremont Avenue East Orange, NJ 07018-1023 is seeking to purchase SomnoFlo Electronic Vaporizer Systems Brand Name or Equal. Please see attached solicitation for additional details. | Combined Synopsis | 334516 | No Set-Aside | 09/09/2026 | 09/18/2026 | East Orange, NJ | |
INTENT TO SOLE SOURCE AND JUSTIFICATION | Special Notice | 334516 | No Set-Aside | 08/18/2026 | 08/25/2026 | Cleveland, OH |
Additional Details
Solicitation Number
FY26-0778
Archive Date
Jul 2, 2026
Office Address
FORT DETRICK, MD, 21702